Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kyorin HD: Double-Digit Growth in Sales, Profits Driven by Kipres
June 6, 2011
- Chugai Applies for Pediatric Use, Dosage of CellCept
June 6, 2011
- Kaken: Operating Profits Up 20%
June 6, 2011
- BM Files for Breast Cancer for Paraplatin Based on Public Knowledge
June 6, 2011
- Mochida: Net Profits Down 46% due to Earthquake
June 6, 2011
- Korosho Designates Velaglucerase Alfa as Orphan Drug for Gaucher's Disease
June 6, 2011
- Kissei: Sales Up 3.6% Driven by Major Products Including Urief
June 6, 2011
- 17 Companies to List Actos Generics in June, 9 to Delay Listing
June 6, 2011
- Takeda to Acquire Nycomed for 9.6 Bil. Euros
May 30, 2011
- JMA Formally Requests Postponement of Medical, Nursing Fee Revisions
May 30, 2011
- Top-10 Domestic Drug Makers' Sales, Profits Down due to Patent Expirations
May 30, 2011
- “Strict Warning”Issued to MSD for 4 Violations of Fair Promotion Code
May 30, 2011
- MTPC: Sales Up 1.2%, Double-digit Growth in Profits
May 30, 2011
- Asahi Kasei Pharma Obtains Marketing Approval for Flivas in South Korea
May 30, 2011
- DSP: Sales Up 28.1% through Acquisition of Sunovion of US
May 30, 2011
- Eisai's Novel Anticancer Drug Halaven Approved in Switzerland
May 30, 2011
- Shionogi: Net Profits Down 48.2% due to Earthquake, US Restructuring
May 30, 2011
- Ajinomoto, Mochida to Codevelop Fixed Dose CCB + ARB Combination from PIII
May 30, 2011
- Taisho: Operating Profits Up 27% due to Decreases in SGA Expenses
May 30, 2011
- Sales Down 0.5% due to Slump of Existing Products: Ono
May 30, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…